Dampening the drawbacks of elevated antigen-specific IFN-γ secretion by CD4+ T cells without affecting the protective IFN-γ response is a difficult challenge in TB research, particularly to generate a strongly immunogenic though safe vaccine. The gene discussed is IFNG; the disease is tuberculosis.